Ameliorative Effect of Probiotic Supplementation on Intestinal Barrier Function in the Healthy Population

Self-Controlled Study on the Ameliorative Effect of Probiotic Supplementation on Intestinal Barrier Function in the Healthy Population

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500113720

Enrollment

Unknown

Registered

2025-12-02

Start date

2025-12-15

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gut Barrier Dysfunction

Interventions

Healthy Young Control Group:None

Older Adult Group:Orally administered triple viable probiotic tablets (containing Lactobacillus and Bifidobacterium)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Young Control Group: Aged 18-60 years. Older Adult Group: Aged 60-85 years. 2. Provision of informed consent.

Exclusion criteria

Exclusion criteria: 1. Concomitant severe cardiac, hepatic, pulmonary, renal, hematologic, endocrine, neurological, or autoimmune diseases. 2. Active respiratory, gastrointestinal, or urinary tract infections. 3. History of abdominal surgery (excluding appendectomy). 4. Recent use (within 1 month) of antibiotics or systemic corticosteroids. 5. Recent use (within 2 weeks) of intestinal microecological agents, laxatives, or antidiarrheal drugs for >3 consecutive days. 6. Pregnancy or lactation. 7. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).

Design outcomes

Primary

Measure	Time frame
Lipopolysaccharide binding protein, LBP;Zonulin;Gut microbiota metagenome;metabolomics;	—

Countries

China

Contacts

Public ContactWei Fu

Peking University Third Hospital

fuwei@bjmu.edu.cn+86 139 1109 8483

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026